How Oregon is tackling high drug costs.
The Oregon Division of Financial Regulation published a list of the top 25 most-expensive prescription drugs in Oregon this week.
These are the drugs that “contribute the most to annual spending by health insurance companies,” according to OregonLive.com
According to Oregon.gov, Oregon’s Prescription Drug Price Transparency Program requires health insurance companies to report on prescription drugs in Oregon. Health insurance companies reported the 25 most prescribed drugs, the 25 most costly prescription drugs, and the 25 prescription drugs which caused the biggest increases in yearly health plan spending in 2018.
Related: Drug Prices, Shortages Remain Problem
The five costliest drugs for healthcare insurance companies are:
“The cost of these newer therapies have garnered quite a bit of attention over the past several years. These drugs were approved on the premise that they provide clinical benefit for patients with serious and chronic conditions and work best when used appropriately and consistently,” says Jerry Buller, chief pharmacy officer at Trellis Rx, a health system specialty pharmacy service partner.
The high-touch specialty pharmacy service model employed by Legacy Health in Portland is an example of a health system initiative to improve adherence to these medications, which can enhance clinical outcomes and prevent disease progression (e.g., stop progression of HCV to liver cancer) or unnecessary medical events (e.g., surgery), according to Buller.
“The embedded specialty pharmacy model also serves to elevate the role of pharmacy on care teams to ensure these high-cost medications are being used appropriately and effectively,” he says.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen